Skip to main content
Figure 6 | BMC Medicine

Figure 6

From: A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

Figure 6

All Evidence network: PFS over time for each group of treatments as obtained with random effects Weibull network meta-analysis model with time-varying hazard ratios (up to 40 months). CD, cyclophosphamide + doxorubicin; CMF, cyclophosphamide + methotrexate + 5-fluorouracil; CT, chemotherapy; HT, hormonal therapy; MA, megestrol acetate; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us